Results 101 to 110 of about 2,265 (188)

Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

COPD
Background Despite limited breakthroughs in COPD pharmacotherapy, recent trials have shown promising results for biologics in COPD patients. However, robust evidence synthesis in this area is currently lacking.Methods We conducted a systematic review of ...
Tyler Pitre, Daniel Lupas, Jasmine Mah, Matthew Stanbrook, Alina Blazer, Dena Zeraatkar, Terence Ho   +6 more
doaj   +1 more source

Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways. [PDF]

The etiology of allergy is closely linked to type 2 inflammatory responses ultimately leading to the production of allergen-specific immunoglobulin E (IgE), a key driver of many allergic conditions.
Eggel, Alexander, Jardetzky, Theodore S, Pennington, Luke F   +2 more
core   +1 more source

Efficacy of tezepelumab against uncontrolled severe non‐type 2 asthma refractory to bronchial thermoplasty, benralizumab, dupilumab and mepolizumab

Respirology Case Reports
Severe asthma affects approximately 5%–10% of patients with asthma. Herein, we describe a case of non‐type 2 asthma that progressively worsened over the years. An 80‐year‐old woman was diagnosed with asthma 11 years back.
Yoshiro Kai, Kentaro Suzuki, Ryosuke Kataoka, Ichiro Sato, Shinji Tamaki, Shigeo Muro   +5 more
doaj   +1 more source

Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study [PDF]

INTRODUCTION: Many patients with severe asthma continue to experience symptoms and exacerbations despite treatment with standard-of-care therapy. In the phase 3 NAVIGATOR study, tezepelumab significantly reduced exacerbations over 52 weeks compared with ...
Ambrose, Christopher S, Brusselle, Guy, Burke, Luke K, Carr, Tara F, Castro, Mario, Chandarana, Shradha, Chupp, Geoffrey L, Hunter, Gillian, Kraft, Monica, Lindsley, Andrew W, Llanos, Jean-Pierre, Moore, Wendy C, Wechsler, Michael E   +12 more
core   +1 more source

The last step to achieve barrier damage control [PDF]

Heterogeneity characterises inflammatory diseases and different phenotypes and endotypes have been identified. Both innate and adaptive immunity contribute to the immunopathological mechanism of these diseases and barrier damage plays a prominent role ...
Caruso, Cristiano, Colantuono, Stefania, Gasbarrini, Antonio, Papa, Alfredo   +3 more
core   +1 more source

Adverse effects of monoclonal antibodies in the treatment of moderate-to-severe asthma: a narrative review [PDF]

Introduction and purpose: Over the past two decades, the management of severe asthma shifted from high doses of inhaled and oral corticosteroids to targeted biologic agents.
Boczar, Agata, Dryja, Patryk, Jarmołowicz, Jakub, Orzołek, Izabela, Stawicka, Izabela   +4 more
core   +1 more source

The Role of Biologics in Reducing Mucous Plug Burden in Asthma [PDF]

Asthma is a chronic inflammatory respiratory disease, affecting hundreds of millions of individuals worldwide. Mucous hypersecretion, which leads to the formation of mucous plugs within the airways, is a key pathophysiological feature associated with ...
Canonica, G. Walter, Chan, Rory, Pelaia, Corrado, Poto, Remo, Varricchi, Gilda, Virchow, J. Christian   +5 more
core   +1 more source

Biomarkers and clinical outcomes after tezepelumab cessation

Annals of Allergy, Asthma & Immunology
Background: Long-term tezepelumab treatment in the DESTINATION study (NCT03706079) resulted in reduced asthma exacerbations, reduced biomarker levels, and improved lung function and symptom control in patients with severe, uncontrolled asthma. Objective: To explore the time course of changes in biomarkers and clinical manifestations after treatment ...
Brightling, Christopher E., Caminati, Marco, Llanos, Jean-Pierre, Caveney, Scott, Kotalik, Ales, Griffiths, Janet M., Lundahl, Anna, Israel, Elliot, Pavord, Ian D., Wechsler, Michael E., Porsbjerg, Celeste, Corren, Jonathan, Gołąbek, Monika, Martin, Neil, Ponnarambil, Sandhia   +14 more
openaire   +2 more sources

Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types

Journal of Asthma and Allergy
Reynold Panettieri Jr,1 Njira Lugogo,2 Jonathan Corren,3 Christopher S Ambrose4 1Rutgers Institute for Translational Medicine and Science, Rutgers University, New Brunswick, NJ, USA; 2Michigan Medicine Asthma Program, University of Michigan, Ann Arbor ...
Panettieri R Jr, Lugogo N, Corren J, Ambrose CS   +3 more
doaj  

Severe Paediatric Asthma Collaborative in Europe: real-world data on children on biologics [PDF]

Asma pediátrica grave; Niños; Medicamentos biológicosAsma pediàtrica greu; Nens; Medicaments biològicsSevere paediatric asthma; Children; Biologics drugsIntroduction Real-world data on children with severe asthma is scarce.
Adalen, Sigve, Amat, Flore, Bravo López, Maynor Guillermo, de Mir Messa, Ines, Deschildre, Antoine, Liu, Norrice, Pijnenburg, Mariëlle W.   +6 more
core   +1 more source